These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 25918937)

  • 21. Site-directed mutant p21 proteins defective in both inhibition of E2F-regulated transcription and disruption of E2F-p130-cyclin-cdk2 complexes.
    Robles SJ; Shiyanov P; Aristodemo GT; Raychaudhuri P; Adami GR
    DNA Cell Biol; 1998 Jan; 17(1):9-18. PubMed ID: 9468218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential phosphorylation patterns between the Cyclin-A2/CDK2 complex and their monomers.
    Casado-Vela J; Martínez-Torrecuadrada JL; Casal JI
    Protein Expr Purif; 2009 Jul; 66(1):15-21. PubMed ID: 19233286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
    Chohan TA; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Molecular dynamics modeling of the substitution of serine for the conservative glycine in the G loop in the yeast cdc28-srm mutant using the crystalline lattice of human kinase CDK2].
    Kholmurodov KhT; Kretov DA; Gerasimova AS; Koltovaia NA
    Biofizika; 2006; 51(4):679-91. PubMed ID: 16909847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor.
    Deng Y; Shipps GW; Zhao L; Siddiqui MA; Popovici-Muller J; Curran PJ; Duca JS; Hruza AW; Fischmann TO; Madison VS; Zhang R; McNemar CW; Mayhood TW; Syto R; Annis A; Kirschmeier P; Lees EM; Parry DA; Windsor WT
    Bioorg Med Chem Lett; 2014 Jan; 24(1):199-203. PubMed ID: 24332088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Network-based modelling and percolation analysis of conformational dynamics and activation in the CDK2 and CDK4 proteins: dynamic and energetic polarization of the kinase lobes may determine divergence of the regulatory mechanisms.
    Verkhivker GM
    Mol Biosyst; 2017 Oct; 13(11):2235-2253. PubMed ID: 28926061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Homology model of the CDK1/cyclin B complex.
    McGrath CF; Pattabiraman N; Kellogg GE; Lemcke T; Kunick C; Sausville EA; Zaharevitz DW; Gussio R
    J Biomol Struct Dyn; 2005 Apr; 22(5):493-502. PubMed ID: 15702922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification and Characterization of an Irreversible Inhibitor of CDK2.
    Anscombe E; Meschini E; Mora-Vidal R; Martin MP; Staunton D; Geitmann M; Danielson UH; Stanley WA; Wang LZ; Reuillon T; Golding BT; Cano C; Newell DR; Noble ME; Wedge SR; Endicott JA; Griffin RJ
    Chem Biol; 2015 Sep; 22(9):1159-64. PubMed ID: 26320860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting Conformational Activation of CDK2 Kinase.
    Pellerano M; Tcherniuk S; Perals C; Ngoc Van TN; Garcin E; Mahuteau-Betzer F; Teulade-Fichou MP; Morris MC
    Biotechnol J; 2017 Aug; 12(8):. PubMed ID: 28430399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ING5 is phosphorylated by CDK2 and controls cell proliferation independently of p53.
    Linzen U; Lilischkis R; Pandithage R; Schilling B; Ullius A; Lüscher-Firzlaff J; Kremmer E; Lüscher B; Vervoorts J
    PLoS One; 2015; 10(4):e0123736. PubMed ID: 25860957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction between the Cdk2/cyclin A complex and a small molecule derived from the pRb2/p130 spacer domain: a theoretical model.
    Giordano A; Bellacchio E; Bagella L; Paggi MG
    Cell Cycle; 2007 Nov; 6(21):2591-3. PubMed ID: 17726381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
    Park H; Yeom MS; Lee S
    Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313.
    Talapati SR; Nataraj V; Pothuganti M; Gore S; Ramachandra M; Antony T; More SS; Krishnamurthy NR
    Acta Crystallogr F Struct Biol Commun; 2020 Aug; 76(Pt 8):350-356. PubMed ID: 32744246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulatory phosphorylation of cyclin-dependent kinase 2: insights from molecular dynamics simulations.
    Bártová I; Koca J; Otyepka M
    J Mol Model; 2008 Aug; 14(8):761-8. PubMed ID: 18470542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of the phospho-CDK2/cyclin A recruitment site in substrate recognition.
    Cheng KY; Noble ME; Skamnaki V; Brown NR; Lowe ED; Kontogiannis L; Shen K; Cole PA; Siligardi G; Johnson LN
    J Biol Chem; 2006 Aug; 281(32):23167-79. PubMed ID: 16707497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular basis for the specificity of p27 toward cyclin-dependent kinases that regulate cell division.
    Lacy ER; Wang Y; Post J; Nourse A; Webb W; Mapelli M; Musacchio A; Siuzdak G; Kriwacki RW
    J Mol Biol; 2005 Jun; 349(4):764-73. PubMed ID: 15890360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism of Cdk2/Cyclin E inhibition by p27 and p27 phosphorylation.
    Xu X; Nakano T; Wick S; Dubay M; Brizuela L
    Biochemistry; 1999 Jul; 38(27):8713-22. PubMed ID: 10393546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein conformational transitions coupled to binding in molecular recognition of unstructured proteins: deciphering the effect of intermolecular interactions on computational structure prediction of the p27Kip1 protein bound to the cyclin A-cyclin-dependent kinase 2 complex.
    Verkhivker GM
    Proteins; 2005 Feb; 58(3):706-16. PubMed ID: 15609350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIRA, the human homologue of yeast Hir1p and Hir2p, is a novel cyclin-cdk2 substrate whose expression blocks S-phase progression.
    Hall C; Nelson DM; Ye X; Baker K; DeCaprio JA; Seeholzer S; Lipinski M; Adams PD
    Mol Cell Biol; 2001 Mar; 21(5):1854-65. PubMed ID: 11238922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
    Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.